For patients diagnosed with advanced kidney cancer, new antiangiogenic treatments are a major advance in the treatment of this disease, compared with the harsher, less effective treatment of the past. Improved outcomes with angiogenesis inhibitors are now common. Therapies that block the growth of tumor blood vessels give patients reason for hope and optimism for this difficult tumor type.

Although there are a number of effective antiangiogenic drugs available for kidney cancer, patients and their families should remember that clinical trials are an important opportunity to gain access to even newer cutting edge cancer therapies. Clinical trials also contribute to the advancement of medical knowledge that can benefit future generations.